Oppenheimer & Co. Inc. Sells 9,310 Shares of Novo Nordisk A/S (NYSE:NVO)

Oppenheimer & Co. Inc. decreased its stake in Novo Nordisk A/S (NYSE:NVO) by 6.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,066 shares of the company’s stock after selling 9,310 shares during the period. Oppenheimer & Co. Inc.’s holdings in Novo Nordisk A/S were worth $11,876,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $28,000. Center for Financial Planning Inc. grew its holdings in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the period. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S during the third quarter worth about $42,000. Dunhill Financial LLC grew its holdings in Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after purchasing an additional 311 shares during the period. Finally, Albion Financial Group UT grew its holdings in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NVO. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Down 1.4 %

Shares of NVO opened at $89.67 on Thursday. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15. The company has a market cap of $402.41 billion, a P/E ratio of 27.26, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a 50 day simple moving average of $84.99 and a two-hundred day simple moving average of $107.30.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is presently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.